Maraviroc for treatment-naive patients with HIV-1 infection: is the glass half empty or half full?
Paul E
PE
Sax
D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes / Q000494:pharmacology / Q000627:therapeutic use*; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy* / Q000517:prevention & control; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D000077592:Maraviroc; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use*
D000998:Antiviral Agents; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D014230:Triazoles; D000077592:Maraviroc